Director Myers Scott Dunseth made open market purchases of Zentalis Pharmaceuticals ($ZNTL) shares once in the last year, totaling about $29,000 on April 30, 2025, ranking 3,457th among insiders. He also bought Dynavax Technologies ($DVAX) shares once for $41,116 on August 22, 2025, ranking 3,209th. Among 4,983 insiders averaging 1.46 million per buyer and 3.29 transactions, Dunseth had no open market sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 10, 2026 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Myers Scott Dunseth | Not found | D | Common Stock - Restricted Stock Units | 31204 | $0.00 | 0.0000 | 136,468,000 | 100.00% | 0.02% |
| Feb. 10, 2026 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Myers Scott Dunseth | Not found | U | Common Stock | 3800 | $0.00 | 0.0000 | 136,468,000 | 100.00% | 0.00% |
| Feb. 10, 2026 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Myers Scott Dunseth | Not found | D | Stock Option (Right to Buy) | 28500 | $0.00 | 0.0000 | 136,468,000 | 100.00% | 0.02% |
| Feb. 10, 2026 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Myers Scott Dunseth | Not found | D | Stock Option (Right to Buy) | 22500 | $0.00 | 0.0000 | 136,468,000 | 100.00% | 0.02% |
| Feb. 10, 2026 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Myers Scott Dunseth | Not found | D | Stock Option (Right to Buy) | 16875 | $0.00 | 0.0000 | 136,468,000 | 100.00% | 0.01% |
| Feb. 10, 2026 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Myers Scott Dunseth | Not found | D | Stock Option (Right to Buy) | 45000 | $0.00 | 0.0000 | 136,468,000 | 100.00% | 0.03% |
| Feb. 10, 2026 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Myers Scott Dunseth | Not found | D | Stock Option (Right to Buy) | 22500 | $0.00 | 0.0000 | 136,468,000 | 100.00% | 0.02% |
| Aug. 22, 2025 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Myers Scott Dunseth | Director | P | Common Stock | 3800 | $10.82 | 35,004.0000 | 133,344,000 | 12.18% | 0.00% |
| June 17, 2025 | Zentalis Pharmaceuticals, Inc. | $ZNTL | Myers Scott Dunseth | Director | A | Common Stock | 57603 | $0.00 | 338,795.0000 | 71,811,508 | 20.49% | 0.08% |
| June 11, 2025 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Myers Scott Dunseth | Director | A | Common Stock | 5758 | $0.00 | 31,204.0000 | 133,344,000 | 22.63% | 0.00% |
| June 11, 2025 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Myers Scott Dunseth | Director | A | Stock Option (Right to Buy) | 28500 | $0.00 | 28,500.0000 | 133,344,000 | 9999.99% | 0.02% |
| April 30, 2025 | Zentalis Pharmaceuticals, Inc. | $ZNTL | Myers Scott Dunseth | Director | P | Common Stock | 21000 | $1.40 | 281,192.0000 | 71,811,508 | 8.07% | 0.03% |
| Nov. 13, 2024 | Zentalis Pharmaceuticals, Inc. | $ZNTL | Myers Scott Dunseth | Director | A | Common Stock | 260192 | $0.00 | 260,192.0000 | 0 | 9999.99% | 0.00% |
| May 23, 2024 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Myers Scott Dunseth | Not found | A | Common Stock | 5357 | $0.00 | 25,446.0000 | 128,733,000 | 26.67% | 0.00% |
| May 23, 2024 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Myers Scott Dunseth | Not found | A | Stock Option (Right to Buy) | 22500 | $0.00 | 22,500.0000 | 128,733,000 | 9999.99% | 0.02% |
| Nov. 13, 2023 | Cartesian Therapeutics, Inc. | $RNAC | Myers Scott Dunseth | Director | D | Stock Option (Right to Buy) | 40000 | $0.00 | 0.0000 | 5,101,459 | 100.00% | 0.78% |
| Nov. 13, 2023 | Cartesian Therapeutics, Inc. | $RNAC | Myers Scott Dunseth | Director | D | Stock Option (Right to Buy) | 87500 | $0.93 | 0.0000 | 5,101,459 | 100.00% | 1.72% |
| Nov. 13, 2023 | Cartesian Therapeutics, Inc. | $RNAC | Myers Scott Dunseth | Director | D | Stock Option (Right to Buy) | 40000 | $0.00 | 0.0000 | 5,101,459 | 100.00% | 0.78% |
| Nov. 13, 2023 | Cartesian Therapeutics, Inc. | $RNAC | Myers Scott Dunseth | Director | D | Stock Option (Right to Buy) | 20000 | $0.00 | 0.0000 | 5,101,459 | 100.00% | 0.39% |
| Nov. 13, 2023 | Cartesian Therapeutics, Inc. | $RNAC | Myers Scott Dunseth | Director | D | Stock Option (Right to Buy) | 20000 | $0.00 | 0.0000 | 5,101,459 | 100.00% | 0.39% |
| Jan. 2, 2023 | Cartesian Therapeutics, Inc. | $RNAC | Myers Scott Dunseth | Director | A | Stock Option (Right to Buy) | 87500 | $0.00 | 87,500.0000 | 5,101,459 | 9999.99% | 1.72% |